Carbamic Acid Patents (Class 560/157)
  • Publication number: 20090192225
    Abstract: Acyloxyalkyl carbamate prodrugs of ?-amino acids, pharmaceutical compositions thereof, methods of making acyloxyalkyl carbamate prodrugs of ?-amino acids and methods of using acyloxyalkyl carbamate prodrugs of ?-amino acids, and pharmaceutical compositions thereof to treat a disease are disclosed. Acyloxyalkyl carbamate prodrugs of ?-amino acids suitable for oral administration using sustained release dosage forms are also disclosed.
    Type: Application
    Filed: April 1, 2009
    Publication date: July 30, 2009
    Applicant: XenoPort, Inc.
    Inventors: Xuedong Dai, Archana Gangakhedkar, Jia-Ning Xiang, Mark A. Gallop
  • Patent number: 7553906
    Abstract: An organic polyisocyanate with at least one unsaturated functional group is capable of copolymerizing when exposed to actinic radiation. The polyisocyanate comprises structural units with the formula (1): wherein: X is an electron-attracting group; R1, and R2 are hydrogen atoms, a saturated or unsaturated aliphatic or cycloaliphatic radical, or an aromatic or araliphatic radical; and n is an integer from 0 to 5. A process for producing this polyisocyanate is also disclosed.
    Type: Grant
    Filed: December 17, 2003
    Date of Patent: June 30, 2009
    Assignee: Bayer MaterialScience AG
    Inventors: Jan Weikard, Christoph Gürtler, Wolfgang Fischer, Diethelm Rappen, Michael Schelhaas
  • Publication number: 20090118368
    Abstract: The present invention discloses compounds of formula (I), their optical isomers or pharmaceutically acceptable salts thereof, their preparation and uses thereof, wherein the definitions of R1, R2, R3 and R4 are shown in the description. These compounds are optical isomers or racemic mixtures. After these compounds are uptaken, they are metabolically transformated in vivo into 1-[2-dimethylamino-1-(4-hydroxyphenyl)-ethyl]-cyclohexanol that has neuropharmacological activity, by interrupting reuptake of 5-hydroxytryptamine (5-HT) and/or norepinephrine (NA), which is used for treating diseases associated with central nerve system, such as depression, etc.
    Type: Application
    Filed: June 16, 2006
    Publication date: May 7, 2009
    Applicants: SHANDONG LUYE PHARMACEUTICAL CO. LTD.
    Inventor: Luping Zhang
  • Patent number: 7520222
    Abstract: Phase change ink carrier compositions comprising an admixture of (1) at least one urethane resin; and/or (2) at least one mixed urethane/urea resin; and/or (3) at least one mono-amide; and/or (4) at least one polyethylene wax are provided. In addition, a phase change colored ink of such carrier compositions comprising a phase change ink compatible colorant are also provided. Embodiments of the present invention also include methods for producing a layer of the above phase change colored ink on the surface of a substrate by either direct or indirect printing. Such methods also encompassing using a polyethylene wax as an overcoat layer above such a phase change ink layer on a printed substrate.
    Type: Grant
    Filed: March 18, 2004
    Date of Patent: April 21, 2009
    Assignee: Xerox Corporation
    Inventors: Donald R. Titterington, Jeffrey H. Banning
  • Publication number: 20090068242
    Abstract: The present invention includes insecticidal carbamates that are useful, for example, for the control of insects, such as mosquitoes, which can be used in applications where exposure to and/or contact with humans is likely. The insecticides of the present invention include phenyl N-methyl carbamates and compositions comprising them that exhibit species-selective inhibition of acetylcholinesterase (AChE) and are preferably toxic to mosquitoes but not humans. Of particular interest are compounds of Formula (I) and Formula (II): Compounds of Formula (I) and Formula (II) are especially suitable for insecticide treated nets and indoor residual spraying for mosquito control.
    Type: Application
    Filed: September 12, 2008
    Publication date: March 12, 2009
    Inventors: Paul Carlier, Jeffrey Bloomquist, Sally Paulson, Eric Wong
  • Patent number: 7498394
    Abstract: The present invention provides novel (meth)acrylic and (meth)acrylamide monomers and polymers produced from those monomers. The monomers of the invention each include only a single vinyl functionality and at least one non-vinyl functionality that can be varied to achieve desired monomer/polymer properties. The invention additionally provides methods of producing polymers from these mono-vinyl monomers.
    Type: Grant
    Filed: February 20, 2004
    Date of Patent: March 3, 2009
    Assignee: The Regents of the University of Colorado
    Inventors: Christopher N. Bowman, Jeffrey W. Stansbury, Kathryn A. Berchtold, Jun Nie
  • Patent number: 7476756
    Abstract: The invention relates to a compound of formula (I): Wherein R1, R2, R3 and R4 are as defined herein. The invention also relates to methods of preparation of compounds of formula (I) as well as to their therapeutic application.
    Type: Grant
    Filed: October 19, 2007
    Date of Patent: January 13, 2009
    Assignee: Sanofi-Aventis
    Inventors: Antonio Almario-Garcia, Pascal George, Christian Hoornaert, Adrien Tak Li, Frederic Puech
  • Publication number: 20080311635
    Abstract: A process for the preparation of (S)(+)-3-(aminomethyl)-5-methylhexanoic acid (pregabalin) of formula (I) or a salt thereof, comprising the reaction of a compound of formula (II) with an alcohol ROH, in the presence or absence of enzyme, to give a compound of formula (III) as herein defined the transformation of a compound of formula (III) into a compound of formula (VI) or (VIII) as herein defined, and the subsequent hydrolysis of a compound of formula (VI) or (VIII), to give pregabalin.
    Type: Application
    Filed: May 13, 2008
    Publication date: December 18, 2008
    Applicant: DIPHARMA FRANCIS s.r.l.
    Inventors: Sergio Riva, Pietro Allegrini, Elena Serafini, Gabriele Razzetti, Simone Mantegazza, Dario Pastorello
  • Publication number: 20080312262
    Abstract: The invention relates to a compound of formula (I): Wherein m, n, X, Y, R1, R2, R3 and R4 are as defined herein. The invention also relates to the use of same in therapeutics.
    Type: Application
    Filed: August 21, 2008
    Publication date: December 18, 2008
    Applicant: SANOFI-AVENTIS
    Inventors: Ahmed Abouabdellah, Antonio Almario Garcia, Jacques Froissant, Christian Hoornaert
  • Publication number: 20080312467
    Abstract: The present invention provides a novel method for preparing a key intermediate, 3-amino-pentan-1,5-diol (2), which is useful for the preparation of 6-(2,4-difluorophenoxy)-2-[3-hydroxy-1-(2-hydroxyethyl)-propylamino]-8-methyl-8H-pyrido[2,3-d]pyrimidine-7-one (1) a MAP-kinase inhibitor useful in the treatment of rheumatoid arthritis.
    Type: Application
    Filed: June 9, 2008
    Publication date: December 18, 2008
    Inventors: Thomas Cleary, Yaohui Ji, Gary R. Lee, Thimma Rawalpally, Keshab Sarma
  • Patent number: 7439257
    Abstract: The invention relates to a compound of formula (I): Wherein m, n, X, Y, R1, R2, R3 and R4 are as defined herein. The invention also relates to the use of same in therapeutics.
    Type: Grant
    Filed: July 11, 2006
    Date of Patent: October 21, 2008
    Assignee: Sanofi-Aventis
    Inventors: Ahmed Abouabdellah, Antonio Almario Garcia, Jacques Froissant, Christian Hoornaert
  • Patent number: 7414145
    Abstract: A method of an enantioselective nucleophilic addition reaction to carbonyl, which enables an asymmetric synthesis of an optically active ?-hydroxy-?-keto acid ester, an optically active ?-hydroxy-?-amino acid ester, hydroxydiketone compounds, etc. being useful as a raw material or synthesis intermediate for producing a pharmaceutical preparation, an agricultural chemical, a fragrance, a functional polymer or the like. In this method, the nucleophilic addition reaction of enamide compound accompanied by hydroxyl (—OH) formation to carbonyl is carried out in the presence of a chiral catalyst with copper or nickel.
    Type: Grant
    Filed: January 24, 2005
    Date of Patent: August 19, 2008
    Assignee: Japan Science and Technology Agency
    Inventor: Shu Kobayashi
  • Patent number: 7405319
    Abstract: The present invention provides an improved process for the preparation of carbamates with high selectivity of pharmaceutical interest by an eco-friendly, non-toxic, phosgene-/isocyanate-/CO-free clean route through a reaction of amine, organic halide compound and carbon dioxide in the presence of a solid, reusable catalyst at moderate conditions and does not require additional cocatalyst/promoter as well as solvent.
    Type: Grant
    Filed: May 22, 2006
    Date of Patent: July 29, 2008
    Assignee: Council of Scientific and Industrial Research
    Inventors: Darbha Srinivas, Rajendra Srivastava, Paul Ratnasamy
  • Patent number: 7335685
    Abstract: Disclosed is crystalline ladostigil tartrate of a specified density, compositions, including pharmaceutical compositions comprising such ladostigil tartrate, and a process for the manufacture thereof.
    Type: Grant
    Filed: February 22, 2006
    Date of Patent: February 26, 2008
    Assignee: TEVA Pharmaceutical Industries, Ltd.
    Inventor: Eliezer Bahar
  • Patent number: 7329773
    Abstract: The invention relates to a process for producing carbamoyloxy (meth)acrylates which comprises transesterification of hydroxyalkyl carbamates with an (meth)acrylate of formula CH2?CR29—COOR30 wherein R29 is hydrogen or methyl and R30 represents an alkyl group comprising from 1 to 8 carbon atoms, in the presence of an organotitanate, an organozirconate catalyst or an organotin catalyst, the carbamoyloxy (meth)acrylates thereby obtained and their use in radiation curable compositions.
    Type: Grant
    Filed: November 18, 2003
    Date of Patent: February 12, 2008
    Assignee: Surface Specialties, S.A.
    Inventors: Vincent Stone, Jurgen Van Holen, Hugues Van Den Bergen
  • Patent number: 7326746
    Abstract: Electron donor compounds, suitable for use as adhesives or as components in adhesives, contain a carbon to carbon double bond attached to an aromatic ring and conjugated with the unsaturation in the aromatic ring.
    Type: Grant
    Filed: February 17, 2005
    Date of Patent: February 5, 2008
    Inventors: Osama M. Musa, Donald E. Herr, Nikola A. Nikolic
  • Patent number: 7323532
    Abstract: The present invention concerns a process for producing low-viscosity polyisocyanates or secondary products thereof, which carry activated, radiation-curable double bonds and can optionally also cure thermally, and low-viscosity polyisocyanate mixtures or secondary products thereof and their use in coating compounds.
    Type: Grant
    Filed: September 29, 2003
    Date of Patent: January 29, 2008
    Assignee: Bayer MaterialScience AG
    Inventors: Thomas Fäcke, Jan Weikard, Wolfgang Fischer
  • Publication number: 20070270605
    Abstract: The present invention provides an improved process for the preparation of carbamates with high selectivity of pharmaceutical interest by an eco-friendly, non-toxic, phosgene-/isocyanate-/CO-free clean route through a reaction of amine, organic halide compound and carbon dioxide in the presence of a solid, reusable catalyst at moderate conditions and does not require additional cocatalyst/promoter as well as solvent
    Type: Application
    Filed: May 22, 2006
    Publication date: November 22, 2007
    Inventors: Darbha Srinivas, Rajendra Srivastava, Paul Ratnasamy
  • Publication number: 20070232806
    Abstract: Hydride process for making acyclic diol intermediates from cyclic intermediates, useful in antibacterial quinolone synthesis.
    Type: Application
    Filed: March 26, 2007
    Publication date: October 4, 2007
    Applicant: The Procter & Gamble Company
    Inventors: Michael Patrick Hayes, Tammy Talbot Schunk
  • Patent number: 7271288
    Abstract: Disclosed is an aromatic compound expressed by the general formula (I), wherein A represents of a fused aromatic hydrocarbon moiety such as triphenylene, X represents a hydrogen-bonding site such as an atomic group containing an amide linkage, Y represents a chain functional group such as an alkyl group having 3 to 18, preferably 10 to 18 carbon atoms, and n represents an integer ranging from 2 to 10. The aromatic compound forms a molecular assembly in which the aromatic rings mutually overlap and exhibits an excellent charge carrier transfer property AX—Y)n.
    Type: Grant
    Filed: December 11, 2003
    Date of Patent: September 18, 2007
    Assignee: Kyushu University, National University Corporation
    Inventors: Masayuki Takeuchi, Masato Ikeda, Seiji Shinkai
  • Patent number: 7268111
    Abstract: The present invention provides angiogenesis inhibitor compounds comprising a MetAP-2 inhibitory core coupled to a peptide, as well as pharmaceutical compositions comprising the angiogenesis inhibitor compounds and a pharmaceutically acceptable carrier. The present invention also provides methods of treating an angiogenic disease, e.g., cancer, in a subject by administering to the subject a therapeutically effective amount of one or more of the angiogenesis inhibitor compounds of the invention.
    Type: Grant
    Filed: September 27, 2005
    Date of Patent: September 11, 2007
    Assignee: Praecis Pharmaceuticals, Inc.
    Inventors: Gary L. Olson, Christopher Self, Lily Lee, Charles M. Cook, Jens Birktoft
  • Patent number: 7220814
    Abstract: The present invention relates to new hydrophilicized blocked polyisocyanates, a process for preparing them and their use.
    Type: Grant
    Filed: December 17, 2003
    Date of Patent: May 22, 2007
    Assignee: Bayer MaterialScience AG
    Inventors: Thorsten Rische, Christoph Gürtler, Karin Naujoks, Thomas Feller
  • Patent number: 7208528
    Abstract: Novel inhibitors of polyamine transport having inhibition constants two orders of magnitude lower than those of known compounds are disclosed. These polyamine analogues are useful pharmaceutical agents for treating diseases where it is desired to inhibit polyamine transport or other polyamine binding proteins, for example cancer and post-angioplasty injury. Novel chemical synthetic methods to obtain polyamine analogues are disclosed, including the production of a combinational polyamine library. These approaches yield analogues with desirable activities both for diagnostic and research assays and therapy. The assays of the invention are useful for high throughput screening of targets in the discovery of drugs that interact with the polyamine system.
    Type: Grant
    Filed: September 15, 1999
    Date of Patent: April 24, 2007
    Assignee: MediQuest Therapeutics, Inc.
    Inventors: Nicolaas M. J. Vermeulin, Christine L. O'Day, Heather K. Webb, Mark R. Burns, Donald E. Bergstrom
  • Patent number: 7164037
    Abstract: Enzymatic preparation of (meth)acrylic esters containing urethane groups, and their use in radiation-curable compositions.
    Type: Grant
    Filed: December 4, 2003
    Date of Patent: January 16, 2007
    Assignee: BASF Aktiengesellschaft
    Inventors: Frank Dietsche, Dietmar Haering, Eva Wagner, Reinhold Schwalm, Heinz-Peter Rink, Erich Beck
  • Patent number: 7160923
    Abstract: Novel inhibitors of polyamine transport having inhibition constants two orders of magnitude lower than those of known compounds are disclosed. These polyamine analogues are useful pharmaceutical agents for treating diseases where it is desired to inhibit polyamine transport or other polyamine binding proteins, for example cancer and post-angioplasty injury. Novel chemical synthetic methods to obtain polyamine analogues are disclosed, including the production of a combinatiorial polyamine library. These approaches yield analogues with desirable activities both for diagnostic and research assays and therapy. The assays of the invention are useful for high throughput screening of targets in the discovery of drugs that interact with the polyamine system.
    Type: Grant
    Filed: November 14, 2000
    Date of Patent: January 9, 2007
    Assignee: MediQuest Therapeutics, Inc.
    Inventors: Nicolaas M. J. Vermeulin, Christine L. O'Day, Heather K. Webb, Mark R. Burns, Donald E. Bergstrom
  • Patent number: 7132565
    Abstract: The present invention provided a norbornene compound with cross-linkable groups and their derivative polymers, wherein said cross-linkable groups were olefin or epoxy groups. Norbornene polymers with cross-linkable side chain and their block copolymers as well as modified derivatives were prepared via living ring-open metathesis polymerization method. The resulting polymers with excellent solubility and optic properties had narrow molecular weight distribution, well-controlled molecular weight, small refraction ration and high transparency. They were also suitable for preparing hybrid materials with high thermal stability and chemical resistance.
    Type: Grant
    Filed: February 13, 2004
    Date of Patent: November 7, 2006
    Assignee: National Taiwan University of Science & Technology
    Inventors: Der-Jang Liaw, Ching-Cheng Huang, Shou-Mau Hong, Ming-Hung Huang
  • Patent number: 7122697
    Abstract: A method for producing carbamates that enables carbamates to be produced at low costs, with high selectivity and high yield, and in a simple manner, and a method for producing isocyanates that enables isocyanates industrially used to be produced by using the carbamates obtained by the carbamates producing method. Nonaromatic amine selected from the group consisting of aliphatic amine, alicyclic amine, and aralkyl amine is allowed to react with alkylaryl carbonate to thereby produce carbamates. Also, the carbamates thus obtained are thermally decomposed to thereby produce isocyanates. When carbamates are produced in this method, alkyl carbamates can be obtained with high selectivity and at high yield by using simple equipment. Also, when isocyanates are produced in this method, polyisocyanates used industrially as the raw material of polyurethane can be produced in a simple manner and with efficiency.
    Type: Grant
    Filed: December 24, 2002
    Date of Patent: October 17, 2006
    Assignee: Mitsui Takeda Chemicals, Inc.
    Inventors: Tsutomu Yoshida, Masaaki Sasaki, Satoshi Kuroiwa, Fumiaki Hirata
  • Patent number: 7115770
    Abstract: The invention concerns the use as catalyst for transforming carbamates of compounds corresponding to the general formula (I): —Sn (X) (X?) wherein: X? is selected among chloride, bromide, iodide, thiocyanate radicals, sulphonate radicals, advantageously perfluorinated on the carbon bearing the sulphonate function; X is selected among the values of X? and among radicals of formula Y-Z; Y is selected among the chalcogen groups, advantageously light (that is oxygen and sulphur); Z is selected in the group consisting of trisubstituted tin, monosubstituted zinc, and the oxygenated acid radicals after ignoring the OH function. The invention is applicable to the coating industry.
    Type: Grant
    Filed: October 8, 2001
    Date of Patent: October 3, 2006
    Assignee: Rhodia-Chimie
    Inventors: Jean-Marie Bernard, Bernard Jousseaume, Christian Laporte, Thierry Toupance
  • Patent number: 7101911
    Abstract: Compounds of the formula I, in which M, A1, A2, K1 and K2 have the meanings given in the description are novel effective tryptase inhibitors.
    Type: Grant
    Filed: February 16, 2002
    Date of Patent: September 5, 2006
    Assignee: Altana Pharma AG
    Inventor: Thomas Martin
  • Patent number: 7084108
    Abstract: The present invention provides angiogenesis inhibitor compounds comprising a MetAP-2 inhibitory core coupled to a peptide, as well as pharmaceutical compositions comprising the angiogenesis inhibitor compounds and a pharmaceutically acceptable carrier. The present invention also provides methods of treating an angiogenic disease, e.g., cancer, in a subject by administering to the subject a therapeutically effective amount of one or more of the angiogenesis inhibitor compounds of the invention.
    Type: Grant
    Filed: November 1, 2001
    Date of Patent: August 1, 2006
    Assignee: Praecis Pharmaceuticals, Inc.
    Inventors: Gary L. Olson, Christopher Self, Lily Lee, Charles Michael Cook, Jens Birktoft, Barry Morgan, Christopher C. Arico-Muendel
  • Patent number: 7081481
    Abstract: Compounds of the formula (I) in which: R1 is (CH2)nY; n is 1 or 2; Y is NHSO2R2 or X1—W—X2—R3; X1 is O or NH; W is C?O, C?S, C?NH, or SO2; X2 is O or NH, provided that X1 and X2 are not both O; R2 is C1-10 alkyl; C2-10 alkenyl; C2-10 alkynyl; aryl; aryl-C1-10 alkyl; aryl-C2-10 alkenyl; aryl-C2-10alkynyl; C3-8 cycloalkyl or C3-8-cycloalkyl-C1-10 alkyl; and R3 is hydrogen, C1-10alkyl; C2-10 alkenyl; C2-10 alkynyl; aryl; aryl-C1-10 alkyl; aryl-C2-10 alkenyl; aryl-C2-10 alkynyl; C3-8 cycloalkyl; or C3-8-cycloalkyl-C1-10 alkyl; or a salt or ester thereof, modulate metabotropic glutamate receptor function and are useful in treating disorders of the central nervous system.
    Type: Grant
    Filed: May 24, 2001
    Date of Patent: July 25, 2006
    Assignee: Eli Lilly and Company
    Inventors: Ivan Collado-Cano, Maria Rosario Gonzalez-Garcia, Beatriz López De Uralde-Garmendia
  • Patent number: 7074852
    Abstract: Blocked polyisocyanates and one-component stoving systems containing these blocked polyisocyanates, and the preparation thereof and their use for the preparation of lacquers, paints, adhesives and elastomers. The blocked polyisocyanates are derived from polyisocyanates reacted with secondary amines and cationic, anionic and/or nonionic hydrophilizing agents such that they are incorporated into the polyisocyanate at a ratio of from 20:1 to 1:1, wherein the blocking agents correspond to the formula R1–R4 can be identical or different and independently of one another denote hydrogen, C1–C6-alkyl or C3–C6-cycloalkyl, R5 denotes C1–C10-alkyl, C3–C10-cycloalkyl, and B represents ?wherein R6–R8 can be identical or different and independently of one another denote C1–C6-alkyl and/or C1–C6-cycloalkyl, R9 denotes hydrogen or C3–C6-alkyl or C3–C6-cycloalkyl.
    Type: Grant
    Filed: June 23, 2004
    Date of Patent: July 11, 2006
    Assignee: Bayer MaterialScience AG
    Inventors: Jan Mazanek, Christoph Thiebes, Jürgen Meixner, Olaf Fleck, Heino Müller
  • Patent number: 7056846
    Abstract: This invention provides compositions and methods for treating fibrous substrates to render those substrates durably repellent to water and oil and durably resistant to dry soil comprising a fluorochemical urethane formed by reacting a tri- or higher order isocyanate with a fluorochemical monofunctional compound; and optionally a non-fluorinated aliphatic monofunctional compound.
    Type: Grant
    Filed: December 4, 2001
    Date of Patent: June 6, 2006
    Assignee: 3M Innovative Properties Company
    Inventors: John C. Clark, Malcolm B. Burleigh, Chetan P. Jariwala, Qiu Zai-Ming
  • Patent number: 7037890
    Abstract: The present invention provides angiogenesis inhibitor compounds comprising a MetAP-2 inhibitory core coupled to a peptide, as well as pharmaceutical compositions comprising the angiogenesis inhibitor compounds and a pharmaceutically acceptable carrier. The present invention also provides methods of treating an angiogenic disease, e.g., cancer, in a subject by administering to the subject a therapeutically effective amount of one or more of the angiogenesis inhibitor compounds of the invention.
    Type: Grant
    Filed: October 5, 2001
    Date of Patent: May 2, 2006
    Assignee: Praecis Pharmaceuticals, Inc.
    Inventors: Gary L. Olson, Christopher Self, Lily Lee, Charles Michael Cook, Jens Birktoft
  • Patent number: 7033522
    Abstract: A blocked polyisocyanate adduct including 5 to 95% by weight of at least one isocyanate component having at least one NCO group, the isocyanate component selected from the group consisting of aliphatic, cycloaliphatic and aromatic isocyanates, wherein the isocyanate has an average molecular weight of up to 1000 g/mol and an average NCO functionality of 2–4; 5 to 70% by weight of at least one hydrophilicizing component containing at least one group which is reactive toward the at least one NCO group; at least one blocking agent for blocking from 95 to 100% of the NCO groups which do not react with the hydrophilicizing component; and up to 15% by weight of at least one neutralizing agent.
    Type: Grant
    Filed: September 27, 2001
    Date of Patent: April 25, 2006
    Assignee: Degussa AG
    Inventors: Klaus-Peter Jonderko, Klaus Janischewski, Lutz Mindach
  • Patent number: 7034185
    Abstract: Disclosed are colorant precursor compounds of the formula wherein R is an alkyl group, an aryl group, an arylalkyl group, or an alkylaryl group, and wherein R can be joined to the phenyl moiety to form a ring, each R?, independently of the others, is a halogen atom, an alkyl group, an alkoxy group, a nitrile group, a nitro group, an amide group, or a sulfonamide group, z is an integer of 0, 1, 2, 3, or 4, n is an integer representing the number of carbon atoms in each repeat alkylene oxide unit, and x is an integer representing the number of repeat alkylene oxide units, wherein said colorant precursor has no more than one —OH, —SH, or primary or secondary amino group per molecule.
    Type: Grant
    Filed: April 24, 2003
    Date of Patent: April 25, 2006
    Assignee: Xerox Corporation
    Inventors: Jeffery H. Banning, Donald R. Titterington, Clifford R. King
  • Patent number: 7026515
    Abstract: A readily available and inexpensive natural ?-amino acid is converted into a compound represented by formula (1), which is then reacted with an organometallic reagent represented by formula (2) to give an optically active 5-hydroxyoxazolidine represented by formula (3), which is then treated with an acid to provide an optically active aminoketone represented by formula (4). The product is then converted into an optically active aminoalcohol represented by formula (5) or (6) by, for example reduction.
    Type: Grant
    Filed: November 9, 2001
    Date of Patent: April 11, 2006
    Assignee: Mitsui Chemicals, Inc.
    Inventors: Hidetoshi Tsunoda, Kunio Okumura, Kengo Otsuka
  • Patent number: 6998364
    Abstract: The invention concerns a novel catalyst for forming urethanes. Said catalyst is characterized by the general formula: MY3?q[Z]q, wherein: Z is the radical corresponding to the anion of a super acid whereof the Hamett constant is at least equal to 13 and advantageously more than 13, M representing a trivalent metal, preferably known for forming Lewis acids; Y is an anion or a monovalent anionic function; and q is an integer selected advantageously between 1 and 3, inclusively. The invention is applicable to paint.
    Type: Grant
    Filed: October 11, 2001
    Date of Patent: February 14, 2006
    Assignee: Rhodia Chimie
    Inventors: Jean-Marie Bernard, Bernard Jousseaume, Christian Laporte, Thierry Toupance
  • Patent number: 6982348
    Abstract: The present invention provides a pharmaceutical agent having cholesteryl ester transfer protein inhibitory action and useful as a blood lipid lowering agent and the like. The present invention relates to a compound represented by the formula wherein Ar1 is an aromatic ring group optionally having substituents, Ar2 is an aromatic ring group having substituents, OR? is an optionally protected hydroxyl group, R is an acyl group, R? is a hydrogen atom or a hydrocarbon group optionally having substituents, or a salt thereof, and a pharmaceutical composition containing a compound of the formula (I) or a salt thereof or a prodrug thereof.
    Type: Grant
    Filed: January 25, 2002
    Date of Patent: January 3, 2006
    Assignee: Takeda Pharmaceutical Company Limited
    Inventors: Masakuni Kori, Kazumasa Hamamura, Hiromitsu Fuse, Toshihiro Yamamoto
  • Patent number: 6977309
    Abstract: Provided is a compound having one or more structures of the formula: wherein X is a primary carbamate group, Y is a hydroxy or halide group, n is an integer of 2 or more, n? is an integer of 1 or more, and R0, R1, R2, R3, R4 and R5 may be H or a group selected from alkyl groups, aliphatic groups, cycloaliphatic groups, aromatic groups and mixtures thereof, with the provisos that at least one R1 or R2 group is selected from the group consisting of aliphatic groups, cycloaliphatic groups, and aromatic groups, and in substantially all structures primary carbamate group X is attached to a carbon atom having a lower degree of substitution than a carbon atom to which functional group Y is attached. The invention provides a method of making the claimed compound.
    Type: Grant
    Filed: October 31, 2002
    Date of Patent: December 20, 2005
    Assignee: BASF Corporation
    Inventors: Walter H. Ohrbom, Craig S. Schang
  • Patent number: 6972341
    Abstract: The present invention provides prodrugs of GABA analogs, pharmaceutical compositions of prodrugs of GABA analogs and methods for making prodrugs of GABA analogs. The present invention also provides methods for using prodrugs of GABA analogs and methods for using pharmaceutical compositions of prodrugs of GABA analogs for treating or preventing common diseases and/or disorders.
    Type: Grant
    Filed: June 10, 2003
    Date of Patent: December 6, 2005
    Assignee: Xeno Port, Inc.
    Inventors: Mark A. Gallop, Kenneth C. Cundy, Cindy X. Zhou, Fayang G. Qiu, Fenmei Yao, Jia-Ning Xiang, Ian R. Ollman
  • Patent number: 6908957
    Abstract: Electron donor compounds, suitable for use as adhesives or as components in adhesives, contain a carbon to carbon double bond attached to an aromatic ring and conjugated with the unsaturation in the aromatic ring.
    Type: Grant
    Filed: August 3, 2001
    Date of Patent: June 21, 2005
    Assignee: National Starch and Chemical Investment Holding Corporation
    Inventors: Osama M. Musa, Donald E. Herr, Nikola A. Nikolic
  • Patent number: 6894139
    Abstract: Catalysts contain, as structural units, at least one tertiary amino group and at least one group which, after its decomposition, is capable of complexing or protonating the tertiary amino group.
    Type: Grant
    Filed: July 4, 2001
    Date of Patent: May 17, 2005
    Assignee: BASF Aktiengesellschaft
    Inventors: Martin Kreyenschmidt, Hauke Malz, Dieter Rodewald, Thomas Flug, Ansgar Frericks
  • Patent number: 6888028
    Abstract: Using at least one compound selected from the group consisting of a zirconyl compound and a zirconium alcoholate as an allophanation catalyst, an allophanate group-containing polyisocyanate composition is produced from a starting material of at least one isocyanate compound selected from the group consisting of an aliphatic diisocyanate, an alicyclic diisocyanate and an isocyanate pre-polymer obtained therefrom, and another starting material of a hydroxyl group-containing compound.
    Type: Grant
    Filed: October 16, 2001
    Date of Patent: May 3, 2005
    Assignee: Asahi Kasei Kabushiki Kaisha
    Inventors: Shinichiro Watanabe, Kunio Naoi
  • Publication number: 20040248776
    Abstract: More efficient and/or economical methods for synthesizing heptapeptide alcohol analogs of oxytocin are provided along with novel intermediates which are useful in synthesizing such oxytocin analogs. Efficient and economical methods for synthesizing intermediates useful in synthesizing these oxytocin analogs are also provided.
    Type: Application
    Filed: July 8, 2004
    Publication date: December 9, 2004
    Applicant: Ferring B.V.
    Inventors: Kazimierz Wisniewski, Jacek Stalewski, Guangcheng Jiang
  • Publication number: 20040242572
    Abstract: The present invention relates to carboxamide compounds of general formula I 1
    Type: Application
    Filed: August 22, 2003
    Publication date: December 2, 2004
    Applicant: Boehringer Ingelheim International GmbH
    Inventors: Dirk Stenkamp, Martin Lenter, Heike-Andrea Wieland, Klaus Rudolf, Stephan George Mueller, Ralf R.H. Lotz, Kirsten Arndt, Philipp Lustenberger, Thorsten Lehmann-Lintz
  • Publication number: 20040242915
    Abstract: In one aspect, the invention provides a solid catalyst comprising an active alumina catalyst impregnated with a metal hydroxide. In another aspect, the invention provides a process for preparing the inventive alumina catalyst. In certain embodiments, the catalyst may be used for the protection of amines, alcohols and thiols with a wide variety of protecting agents. This procedure is widely applicable for N-protection of amino acids which finds wide industrial applications. The catalyst is also useful for carrying out nucleophilic substitutions of aromatic halides containing an electron-withdrawing group. A wide variety of nucleophiles chosen from amines, primary and secondary, aromatic and aliphatic, as well as alcohols and thiols have been successfully employed. The methodology involves simple techniques and easy work up procedures and is thus useful for large-scale industrial preparations. Additionally, the reactions avoid the use of harmful solvents and thus satisfy the need for green chemistry.
    Type: Application
    Filed: March 17, 2004
    Publication date: December 2, 2004
    Inventors: Sumitra Srinath, Madhavan Sridharan, Ganesh Sambasivam
  • Publication number: 20040214258
    Abstract: A mutant hydrolase optionally fused to a protein of interest is provided. The mutant hydrolase is capable of forming a bond with a substrate for the corresponding nonmutant (wild-type) hydrolase which is more stable than the bond formed between the wild-type hydrolase and the substrate. Substrates for hydrolases comprising one or more functional groups are also provided, as well as methods of using the mutant hydrolase and the substrates of the invention. Also provided is a fusion protein capable of forming a stable bond with a substrate and cells which express the fusion protein.
    Type: Application
    Filed: January 30, 2004
    Publication date: October 28, 2004
    Inventors: Keith V. Wood, Dieter Klaubert, Georgyi V. Los, Robert F. Bulleit, Mark McDougall, Chad Zimprich
  • Patent number: 6803481
    Abstract: The present invention concerns the use of compounds of the Formula (I) for treating different types and symptoms of acute and chronic pain, especially non neuropathic inflammatory pain in mammals. The pain to be treated may be e.g. chronic inflammatory pain, rheumatoid arthritis pain and/or secondary inflammatory osteoarthritic pain. The compounds show an antinociceptive profile and differ from classical analgesics like opioids and non-steroidal anti-inflammatory drugs (NSAIDS) and are useful as specific analgesics.
    Type: Grant
    Filed: February 11, 2003
    Date of Patent: October 12, 2004
    Assignee: Schwarz Pharma AG
    Inventor: Norma Selve
  • Patent number: 6803378
    Abstract: Novel diketoacid compounds of Formula I are provided which are useful as HIV integrase inhibitors and for the treatment of AIDS or ARC.
    Type: Grant
    Filed: September 25, 2002
    Date of Patent: October 12, 2004
    Assignee: Bristol-Myers Squibb Company
    Inventors: Michael A. Walker, Timothy D. Johnson, Nicholas A. Meanwell, Jacque Banville